Pricing Log in Create free account
Friday 6 November 2026 Export BDX’s income statement to Excel — free account

Becton, Dickinson and Company

BDX Healthcare Medical Instruments & Supplies

Revenue
−10.5%
EPS
+48.5%
Free cash flow
−31.6%
Total debt
−23.8%

Quarter to September 2026, against a year earlier

212.21 1.34 −0.63%
Market cap
$58.2B
P/E
51.1×
Fwd P/E
39.2×
Dividend yield
1.87%
F-score
6/9
Altman Z
n/a
Beneish M
−2.76
Dividend safety
51/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Becton, Dickinson and Company 10-Q filed Aug 7, 2025

Fiscal Q3 2025 · Period ended Jun 30, 2025 · Filed · accepted 4:26 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 1, 2025: 7 added · 6 removed · 60 modified; 33 with only figures updated

  1. Removed · BD’s Intention to Separate Biosciences and Diagnostic Solutions

    On February 5, 2025, we announced our intention to separate our Biosciences and Diagnostic Solutions business from the rest of BD. BD’s board of directors is committed to exploring all opportunities to execute the separation in a manner that maximizes shareholder value, including possible options such as a spin-off, sale, Reverse Morris Trust or other transaction. BD expects to announce more specifics on the separation plans by the end of fiscal year 2025 and intends to target completion of the transaction in fiscal year 2026.